Omar Abdel-Rahman1. 1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address: omar.abdelrhman@med.asu.edu.eg.
Abstract
OBJECTIVE: To assess the impact of delay in initiation of adjuvant chemotherapy and/or radiotherapy on the outcomes of breast cancer patients referred for adjuvant treatment. METHODS: This is a pooled analysis of patient-level data of 3390 breast cancer patients referred for adjuvant chemotherapy in three clinical trials. Overall and relapse-free survivals were assessed according to "surgery to chemotherapy interval" through Kaplan-Meier analysis. Likewise, among patients who received adjuvant radiotherapy, relapse-free survival was assessed according to "surgery to radiotherapy interval" through Kaplan-Meier analysis. Univariate and Multivariate analysis of factors affecting overall and relapse-free survival was then conducted through Cox regression analysis. RESULTS: Kaplan-Meier analysis of overall survival according to surgery to chemotherapy interval (<vs. > 6 weeks) was conducted. When stratified by the hormone receptor status, the longer interval was associated with worse overall survival in hormone receptor-negative patients (P = 0.006); while it was not associated with overall survival difference in hormone receptor-positive patients (P = 0.268). In multivariate Cox regression analysis, the test of interaction between "surgery to chemotherapy interval" and hormone receptor status was significant (P = 0.015). Moreover, when the multivariate analysis was restricted to hormone receptor-negative patients, longer surgery to chemotherapy interval was associated with worse overall survival among this subset of patients (P = 0.004). On the other hand, in multivariate analysis of factors affecting relapse-free survival, surgery to radiotherapy interval did not impact relapse-free survival (P = 0.439). CONCLUSION: Among hormone receptor-negative patients, delaying chemotherapy initiation beyond 6 weeks (after surgery) is associated with worse patient outcomes. Moreover, delaying radiotherapy initiation beyond surgery does not compromise outcomes in patients receiving long course adjuvant chemotherapy.
OBJECTIVE: To assess the impact of delay in initiation of adjuvant chemotherapy and/or radiotherapy on the outcomes of breast cancerpatients referred for adjuvant treatment. METHODS: This is a pooled analysis of patient-level data of 3390 breast cancerpatients referred for adjuvant chemotherapy in three clinical trials. Overall and relapse-free survivals were assessed according to "surgery to chemotherapy interval" through Kaplan-Meier analysis. Likewise, among patients who received adjuvant radiotherapy, relapse-free survival was assessed according to "surgery to radiotherapy interval" through Kaplan-Meier analysis. Univariate and Multivariate analysis of factors affecting overall and relapse-free survival was then conducted through Cox regression analysis. RESULTS: Kaplan-Meier analysis of overall survival according to surgery to chemotherapy interval (<vs. > 6 weeks) was conducted. When stratified by the hormone receptor status, the longer interval was associated with worse overall survival in hormone receptor-negative patients (P = 0.006); while it was not associated with overall survival difference in hormone receptor-positive patients (P = 0.268). In multivariate Cox regression analysis, the test of interaction between "surgery to chemotherapy interval" and hormone receptor status was significant (P = 0.015). Moreover, when the multivariate analysis was restricted to hormone receptor-negative patients, longer surgery to chemotherapy interval was associated with worse overall survival among this subset of patients (P = 0.004). On the other hand, in multivariate analysis of factors affecting relapse-free survival, surgery to radiotherapy interval did not impact relapse-free survival (P = 0.439). CONCLUSION: Among hormone receptor-negative patients, delaying chemotherapy initiation beyond 6 weeks (after surgery) is associated with worse patient outcomes. Moreover, delaying radiotherapy initiation beyond surgery does not compromise outcomes in patients receiving long course adjuvant chemotherapy.
Authors: Catherine Duggan; Allison Dvaladze; Anne F Rositch; Ophira Ginsburg; Cheng-Har Yip; Susan Horton; Rolando Camacho Rodriguez; Alexandru Eniu; Miriam Mutebi; Jean-Marc Bourque; Shahla Masood; Karla Unger-Saldaña; Anna Cabanes; Robert W Carlson; Julie R Gralow; Benjamin O Anderson Journal: Cancer Date: 2020-05-15 Impact factor: 6.860
Authors: Devon Livingston-Rosanoff; Bret Hanlon; Nicholas Marka; Kara Vande Walle; Trista Stankowski-Drengler; Jessica Schumacher; Caprice C Greenberg; Heather Neuman; Lee G Wilke Journal: Breast J Date: 2019-09-12 Impact factor: 2.431
Authors: Debora de Melo Gagliato; Xiudong Lei; Sharon H Giordano; Vicente Valero; Carlos H Barcenas; Gabriel N Hortobagyi; Mariana Chavez-MacGregor Journal: Oncologist Date: 2020-07-07
Authors: Tracy A Battaglia; Karen M Freund; Jennifer S Haas; Nicole Casanova; Sharon Bak; Howard Cabral; Rachel A Freedman; Karen Burns White; Stephenie C Lemon Journal: Contemp Clin Trials Date: 2020-04-17 Impact factor: 2.226
Authors: Nicole M Melchior; Darren B Sachs; Gabrielle Gauvin; Cecilia Chang; Chihsiung E Wang; Elin R Sigurdson; John M Daly; Allison A Aggon; Shelly B Hayes; Elias I Obeid; Richard J Bleicher Journal: Cancer Med Date: 2020-02-25 Impact factor: 4.452